Krystal Biotech, Inc. (FRA:4KB)

Germany flag Germany · Delayed Price · Currency is EUR
189.45
+3.65 (1.96%)
At close: Dec 5, 2025
7.43%
Market Cap 5.84B
Revenue (ttm) 318.05M
Net Income (ttm) 169.53M
Shares Out n/a
EPS (ttm) 5.68
PE Ratio 34.42
Forward PE 27.27
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 19
Open 189.45
Previous Close 185.80
Day's Range 189.45 - 189.45
52-Week Range 108.40 - 189.45
Beta n/a
RSI 66.57
Earnings Date Feb 13, 2026

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 275
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4KB
Full Company Profile

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Financial numbers in USD Financial Statements

News

There is no news available yet.